D. Tutkunkardas

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

J. Gundgaard, N. Thalange, W. Parekh, 2019, BMJ Open Diabetes Research & Care.

Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)

B. Zinman, S. Heller, T. Pieber, 2019, Diabetes, obesity & metabolism.

Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK

H. Kitchen, N. Aldhouse, N. Thalange, 2017, Diabetes Therapy.

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

J. Buse, J. Gundgaard, E. Magnuson, 2019, Applied Health Economics and Health Policy.

Clinical inertia in basal insulin-treated patients with type 2 diabetes – Results from a retrospective database study in Japan (JDDM 43)

M. Andersen, H. Maegawa, J. Satoh, 2018, PloS one.

Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets

J. Silverberg, R. Warren, E. Guttman, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes

E. Seaquist, S. Heller, J. Buse, 2019, Diabetes Care.

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK

J. Buse, J. Gundgaard, S. Marso, 2018, Diabetes Therapy.

Rede fi ning Hypoglycemia in Clinical Trials: Validation of De fi nitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes

E. Seaquist, S. Heller, J. Buse, 2020 .